Previous 10 | Next 10 |
Image source: The Motley Fool. Perrigo (NYSE: PRGO) Q3 2019 Earnings Call Nov 06, 2019 , 8:00 a.m. ET Operator Continue reading
Perrigo Company plc (PRGO) Q3 2019 Results Earnings Conference Call November 6, 2019, 08:00 AM ET Company Participants Bradley Joseph - Vice President, Investor Relations Murray Kessler - President and Chief Executive Officer Raymond Silcock - Executive Vice President and Chief F...
Perrigo (NYSE: PRGO ): Q3 Non-GAAP EPS of $1.04 beats by $0.10 ; GAAP EPS of $0.67 beats by $0.09 . Revenue of $1.19B (+5.3% Y/Y) misses by $10M . Shares +0.4% PM. Press Release More news on: Perrigo Company plc, Earnings news and commentary, Healthcare stocks news,
DUBLIN , Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products TM " , today announced financial results for the third quarter ended September 28, 2019. President and CEO Murray S. K...
AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...
Perrigo (NYSE: PRGO ) is scheduled to announce Q3 earnings results on Wednesday, November 6th, before market open. The consensus EPS Estimate is $0.94 (-13.8% Y/Y) and the consensus Revenue Estimate is $1.2B (+6.2% Y/Y). Over the last 2 years, prgo has beaten EPS estimates 88% of the...
In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...
DUBLIN , Oct. 23, 2019 /PRNewswire/ -- As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possible...
Quick Take Phathom Pharmaceuticals ( PHAT ) intends to raise $150 million from an IPO, per an S-1/A registration statement . The company is advancing a drug treatment for GERD, a common gastrointestinal condition. For life science investors with at least a 24-month hold timeframe, the I...
DUBLIN , Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019 . The Company will host a conference call beginning at 8:00 a.m. (EDT) . The...
News, Short Squeeze, Breakout and More Instantly...
Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024 PR Newswire DUBLIN , July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its secon...
2024-07-19 06:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Perrigo Completes Divestment of HRA Pharma Rare Diseases Business PR Newswire DUBLIN , July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it has compl...